Expanded Access for Treatment With Imetelstat

Status Available

Clinical Trial Summary

The objective of this expanded access protocol (EAP) is to provide access to treatment with imetelstat, the Investigational Product (IP), for eligible adult participants diagnosed with very low, low, intermediate risk (by Revised International Prognostic Scoring System, IPSS-R) myelodysplastic syndromes (MDS) who are red blood cell (RBC) transfusion-dependent, have failed to respond or have lost response or are ineligible for ESAs, had not received prior treatment with either a hypomethylating agent or lenalidomide and were non-del(5q), until such time that imetelstat becomes commercially available.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT05937568
Study type	Expanded Access
Source	Geron Corporation
Contact	WEP Clinical
Phone	919-694-5088
Email	GeronEAP@wepclinical.com
Status	Available
Phase

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT05400122` - Natural Killer (NK) Cells in Combination With Interleukin-2 (IL-2) and Transforming Growth Factor Beta (TGFbeta) Receptor I Inhibitor Vactosertib in Cancer	Phase 1
Terminated	`NCT04313881` - Magrolimab + Azacitidine Versus Azacitidine + Placebo in Untreated Participants With Myelodysplastic Syndrome (MDS)	Phase 3
Recruiting	`NCT05088356` - Reduced Intensity Allogeneic HCT in Advanced Hematologic Malignancies w/T-Cell Depleted Graft	Phase 1
Recruiting	`NCT04003220` - Idiopathic Chronic Thrombocytopenia of Undetermined Significance : Pathogenesis and Biomarker
Completed	`NCT02916979` - Myeloid-Derived Suppressor Cells and Checkpoint Immune Regulators' Expression in Allogeneic SCT Using FluBuATG	Phase 1
Active, not recruiting	`NCT03755414` - Study of Itacitinib for the Prophylaxis of Graft-Versus-Host Disease and Cytokine Release Syndrome After T-cell Replete Haploidentical Peripheral Blood Hematopoietic Cell Transplantation	Phase 1
Completed	`NCT00003270` - Chemotherapy, Radiation Therapy, and Umbilical Cord Blood Transplantation in Treating Patients With Hematologic Cancer	Phase 2
Recruiting	`NCT04904588` - HLA-Mismatched Unrelated Donor Hematopoietic Cell Transplantation With Post-Transplantation Cyclophosphamide	Phase 2
Terminated	`NCT04866056` - Jaktinib and Azacitidine In Treating Patients With MDS With MF or MDS/MPN With MF.	Phase 1/Phase 2
Recruiting	`NCT04701229` - Haploinsufficiency of the RBM22 and SLU7 Genes in Del(5q) Myelodysplastic Syndromes
Suspended	`NCT04485065` - Safety and Efficacy of IBI188 With Azacitidine in Subjects With Newly Diagnosed Higher Risk MDS	Phase 1
Recruiting	`NCT04174547` - An European Platform for Translational Research in Myelodysplastic Syndromes
Enrolling by invitation	`NCT04093570` - A Study for Participants Who Participated in Prior Clinical Studies of ASTX727 (Standard Dose), With a Food Effect Substudy at Select Study Centers	Phase 2
Completed	`NCT02508870` - A Study of Atezolizumab Administered Alone or in Combination With Azacitidine in Participants With Myelodysplastic Syndromes	Phase 1
Completed	`NCT04543305` - A Study of PRT1419 in Patients With Relapsed/Refractory Hematologic Malignancies	Phase 1
Recruiting	`NCT05384691` - Efficacy of Luspatercept in ESA-naive LR-MDS Patients With or Without Ring Sideroblasts Who do Not Require Transfusions	Phase 2
Recruiting	`NCT05365035` - A Phase II Study of Cladribine and Low Dose Cytarabine in Combination With Venetoclax, Alternating With Azacitidine and Venetoclax, in Patients With Higher-risk Myeloproliferative Chronic Myelomonocytic Leukemia or Higher-risk Myelodysplastic Syndromes With Excess Blasts	Phase 2
Recruiting	`NCT06008405` - Clinical Trial Evaluating the Safety of the TQB2928 Injection Combination Therapy	Phase 1
Not yet recruiting	`NCT05969821` - Clonal Hematopoiesis of Immunological Significance
Withdrawn	`NCT05170828` - Cryopreserved MMUD BM With PTCy for Hematologic Malignancies	Phase 1